(AKBA) Akebia Ther - Performance 266.1% in 12m
AKBA performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-31.25%
#48 in Peer-Group
Rel. Strength
98.31%
#126 in Stock-Universe
Total Return 12m
266.05%
#4 in Peer-Group
Total Return 5y
-72.17%
#81 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 3.97 USD |
| 52 Week Low | 0.94 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 69.60 |
| Buy/Sell Signal +-5 | -0.47 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: AKBA (266.1%) vs XBI (-10.8%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
2.52% | 66.7% | 77.4% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-11.7% | -9.92% | 139% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
-3.21% | -7.33% | 26.4% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
-0.28% | 31.9% | -4.56% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
0.91% | -10.3% | 0.26% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.3% | 65.1% | -9.72% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
0.02% | 56.7% | -7.85% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
2.86% | 34.5% | 14.3% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: AKBA vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for AKBA
| Total Return (including Dividends) | AKBA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 12.00% | 2.09% | 4.55% |
| 3 Months | 89.58% | 2.27% | 10.78% |
| 12 Months | 266.05% | -10.84% | 14.71% |
| 5 Years | -72.17% | -26.24% | 112.53% |
| Trend Score (consistency of price movement) | AKBA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 26.3% | 18.8% | 79.2% |
| 3 Months | 95.4% | 71.5% | 92.9% |
| 12 Months | 87.4% | -84.3% | 44.2% |
| 5 Years | -39.1% | -52.7% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th77.50 | 9.71% | 7.12% |
| 3 Month | %th96.50 | 85.38% | 71.14% |
| 12 Month | %th98.50 | 310.54% | 219.11% |
| 5 Years | %th59.00 | -62.27% | -86.91% |
FAQs
Does Akebia Ther (AKBA) outperform the market?
Yes,
over the last 12 months AKBA made 266.05%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.84%.
Over the last 3 months AKBA made 89.58%, while XBI made 2.27%.
Performance Comparison AKBA vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
AKBA vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3% | 7.5% | 85.5% | 251% |
| US NASDAQ 100 | QQQ | -3.8% | 6.5% | 83.4% | 251% |
| German DAX 40 | DAX | -2.8% | 12% | 72.6% | 236% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.6% | 7.8% | 87.5% | 248% |
| Hongkong Hang Seng | HSI | -2.5% | 6.2% | 69.8% | 231% |
| India NIFTY 50 | INDA | -2.5% | 9.9% | 85.8% | 266% |
| Brasil Bovespa | EWZ | -4.3% | 4.2% | 61% | 253% |
AKBA vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -4.5% | 5.2% | 78.9% | 237% |
| Consumer Discretionary | XLY | -1.4% | 10.4% | 94.2% | 246% |
| Consumer Staples | XLP | 0.5% | 13.6% | 87.3% | 257% |
| Energy | XLE | 1.4% | 8.5% | 91% | 270% |
| Financial | XLF | -3.1% | 8.9% | 82.5% | 237% |
| Health Care | XLV | -2% | 10% | 92.8% | 271% |
| Industrial | XLI | -2.5% | 8.3% | 78.9% | 242% |
| Materials | XLB | -1% | 10.4% | 86.2% | 263% |
| Real Estate | XLRE | 1.5% | 12% | 88.2% | 254% |
| Technology | XLK | -4.3% | 3.1% | 82.3% | 254% |
| Utilities | XLU | -0.5% | 11.9% | 82.2% | 242% |
| Aerospace & Defense | XAR | -4.9% | 2.1% | 64.1% | 213% |
| Biotech | XBI | -0.8% | 9.9% | 99.5% | 277% |
| Homebuilder | XHB | -1.2% | 5.9% | 96.8% | 265% |
| Retail | XRT | 0.1% | 10.6% | 94.3% | 260% |
AKBA vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 4.3% | 6.88% | 94.8% | 276% |
| Natural Gas | UNG | 9.3% | 21.4% | 100.7% | 274% |
| Gold | GLD | 2% | 14.2% | 65.7% | 225% |
| Silver | SLV | 0.5% | 8.1% | 67% | 244% |
| Copper | CPER | -3.2% | 7.8% | 65.8% | 251% |
AKBA vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -1.7% | 8.4% | 88.7% | 264% |
| iShares High Yield Corp. Bond | HYG | -0.9% | 10.1% | 86.6% | 255% |